Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183777
Title: | Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis |
Author: | Chen, Baixin Guo, Miaolan Peker, Yüksel Salord, Neus Drager, Luciano F. Lorenzi-Filho, Geraldo Tang, Xiangdong Li, Yun |
Keywords: | Síndromes d'apnea del son Trastorns del metabolisme dels lípids Sleep apnea syndromes Lipid metabolism disorders |
Issue Date: | 25-Jan-2022 |
Publisher: | MDPI AG |
Abstract: | Background: Obstructive sleep apnea (OSA) is associated with dyslipidemia. However, the effects of continuous positive airway pressure (CPAP) treatment on lipid profiles are unclear. Methods: PubMed/Medline, Embase and Cochrane were searched up to July 2021. Randomized controlled trials (RCTs) of CPAP versus controls with >= 4 weeks treatment and reported pre- and post-intervention lipid profiles were included. Weighted mean difference (WMD) was used to assess the effect size. Meta-regression was used to explore the potential moderators of post-CPAP treatment changes in lipid profiles. Results: A total of 14 RCTs with 1792 subjects were included. CPAP treatment was associated with a significant decrease in total cholesterol compared to controls (WMD = -0.098 mmol/L, 95% CI = -0.169 to -0.027, p = 0.007, I-2 = 0.0%). No significant changes in triglyceride, high-density lipoprotein nor low-density lipoprotein were observed after CPAP treatment (all p > 0.2). Furthermore, meta-regression models showed that age, gender, body mass index, daytime sleepiness, OSA severity, follow-up study duration, CPAP compliance nor patients with cardiometabolic disease did not moderate the effects of CPAP treatment on lipid profiles (all p > 0.05). Conclusions: CPAP treatment decreases total cholesterol at a small magnitude but has no effect on other markers of dyslipidemia in OSA patients. Future studies of CPAP therapy should target combined treatment strategies with lifestyle modifications and/or anti-hyperlipidemic medications in the primary as well as secondary cardiovascular prevention models. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm11030596 |
It is part of: | Journal of Clinical Medicine, 2022, vol 11, num 3 |
URI: | http://hdl.handle.net/2445/183777 |
Related resource: | https://doi.org/10.3390/jcm11030596 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-11-00596-v2.pdf | 743.08 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License